TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23176668

Group type: EXPERIMENTAL
Intervention: Combined Psychological Intervention (CPI)
Number of subjects: 140
Study: 19887533

Group type: EXPERIMENTAL
Intervention: Cuffed tracheal tubes (Microcuff PET)
Number of subjects: 2246

Group type: COMPARATOR
Intervention: Uncuffed tracheal tubes (Mallinckrodt, Portex, Rüsch, Sheridan)
Number of subjects: 2246
Study: 17485707

Group type: COMPARATOR
Intervention: Single autologous stem-cell transplantation (ASCT) with high-dose melphalan at 200 mg/m2 (arm A)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Double autologous stem-cell transplantation (ASCT) with melphalan at 200 mg/m2 followed by melphalan at 120 mg/m2 and busulfan at 12 mg/kg (arm B)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Single ASCT (arm A)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Double ASCT (arm B)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Overall survival for the whole group (both arms)
Number of subjects: 321
Study: 15172088

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (CE), 0.625 mg, and medroxyprogesterone acetate (MPA), 5 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (E2), 2 mg, and norethisterone acetate (NETA), 1 mg
Number of subjects: 62
Study: 12138526

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for STD recurrence
Number of subjects: 0
Study: 9485125

Group type: EXPERIMENTAL
Intervention: Right lateral decubitus position
Number of subjects: 44

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 44

Group type: COMPARATOR
Intervention: Left lateral decubitus position
Number of subjects: 44
Study: 7911402

Group type: EXPERIMENTAL
Intervention: SCH 434 (loratadine 5 mg and pseudoephedrine sulfate 120 mg)
Number of subjects: 131

Group type: COMPARATOR
Intervention: CTM-D (chlorpheniramine maleate 12 mg and pseudoephedrine sulfate 120 mg)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: SCH 434
Number of subjects: 131
Study: 2679230

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 12
Study: 29526471

Group type: EXPERIMENTAL
Intervention: Nasal high-flow (nHF) therapy
Number of subjects: 278

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 278
Study: 28198590

Group type: EXPERIMENTAL
Intervention: Vonoprazan 40 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Vonoprazan 120 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 26238412

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) exposure in vitro
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: 4-hydroxytamoxifen (4-OHT) exposure in vitro
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Nuclear HER4 protein expression
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Cytoplasmic HER4 protein expression
Number of subjects: 912
Study: 24683779

Group type: EXPERIMENTAL
Intervention: OFL: Phosphoric Acid/Optibond FL/Premise Flow
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: OAO: Optibond All‐In‐One/Premise Flowable
Number of subjects: 50

Group type: COMPARATOR
Intervention: II: Polyacrylic Acid/Fuji II
Number of subjects: 50

Group type: COMPARATOR
Intervention: IX: Polyacrylic Acid/Fuji IX
Number of subjects: 50

Group type: COMPARATOR
Intervention: V: Vertise Flow
Number of subjects: 50
Study: 21879624

Group type: EXPERIMENTAL
Intervention: Group counseling with a focus on verbal interactions
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Perceived verbal interactions
Number of subjects: 42
Study: 18494345

Group type: EXPERIMENTAL
Intervention: LASEK with mitomycin C (MMC) 0.02% applied for 1 minute
Number of subjects: 228

Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: LASEK with MMC
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Both LASEK and LASIK
Number of subjects: 228
Study: 16096441

Group type: EXPERIMENTAL
Intervention: Furosemide with albumin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Furosemide with placebo (control)
Number of subjects: 40
Study: 12027149

Group type: EXPERIMENTAL
Intervention: Home-based strength training with elastic bands, 3 sessions a week for 4 months.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Home-based strength training with elastic bands.
Number of subjects: 10
Study: 10079459

Group type: EXPERIMENTAL
Intervention: Self Psychological Treatment (SPT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation Treatment (COT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control/Nutritional Counseling (C/NC)
Number of subjects: 33
Study: 8616479

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-smokers (control group)
Number of subjects: 62
Study: 2285635

Group type: EXPERIMENTAL
Intervention: 3 mg piretanide bid
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 7137070

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (300 mg daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31328230

Group type: EXPERIMENTAL
Intervention: BERN scoring criteria for microsleep episodes (MSEs)
Number of subjects: 76

Group type: COMPARATOR
Intervention: AASM scoring criteria for microsleep episodes (MSEs)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: BERN scoring criteria
Number of subjects: 76
Study: 31123992

Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 28729473

Group type: EXPERIMENTAL
Intervention: Automated oxygen titration
Number of subjects: 187

Group type: COMPARATOR
Intervention: Manual oxygen titration
Number of subjects: 187
Study: 26190286

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 23415416

Group type: EXPERIMENTAL
Intervention: Fluid management guided by bioimpedance spectroscopy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual clinical practice (Control)
Number of subjects: 156
Study: 21243500

Group type: EXPERIMENTAL
Intervention: sulindac
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: inulin/VSL#3
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: sulindac/inulin/VSL#3
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 17
Study: 19812399

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator (ICD)
Number of subjects: 898

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 898
Study: 17762816

Group type: EXPERIMENTAL
Intervention: Fear avoidance beliefs (FAB)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Low back pain (LBP)
Number of subjects: 661
Study: 15125213

Group type: EXPERIMENTAL
Intervention: Steroids combined with thyroxine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Steroids only
Number of subjects: 60
Study: 12207869

Group type: EXPERIMENTAL
Intervention: Carbatrol (2 x 200 mg capsules), b.i.d. for 5 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tegretol‐XR (400 mg), b.i.d. for 5 days
Number of subjects: 15
Study: 9427920

Group type: EXPERIMENTAL
Intervention: Standard treatment plus iontophoresis of calcitonin gene‐related peptide and vasoactive intestinal polypeptide
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard treatment plus placebo iontophoresis
Number of subjects: 66
Study: 8085219

Group type: EXPERIMENTAL
Intervention: Fluoridated toothpicks (0.80 mg F as NaF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.25 mg F tablet (Fludent)
Number of subjects: 10
Study: 3140631

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 60
Study: 31559483

Group type: EXPERIMENTAL
Intervention: Optimization of medical therapy with sacubitril/valsartan, ivabradine, or both after CRT implantation
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both sacubitril/valsartan and ivabradine
Number of subjects: 182

Group type: COMPARATOR
Intervention: No indication at baseline
Number of subjects: 182
Study: 31212058

Group type: EXPERIMENTAL
Intervention: Excitatory intermittent TBS (iTBS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inhibitory continuous TBS (cTBS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study: 29231603

Group type: EXPERIMENTAL
Intervention: Warm-needling moxibustion treatment for KOA, 40 min per treatment, 12 treatments over 3 weeks.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no treatment for 3 weeks).
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Warm-needling moxibustion treatment for KOA.
Number of subjects: 50
Study: 25957107

Group type: EXPERIMENTAL
Intervention: Taikong Yangxin (Chinese herbal medicine)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study: 23677418

Group type: EXPERIMENTAL
Intervention: Vaginal ascorbic acid (250 mg tablets vaginally at bedtime once a day for 6 days, followed by one tablet per week for 12 weeks)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Vaginal ascorbic acid
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 140
Study: 22260015

Group type: EXPERIMENTAL
Intervention: Bushenhuoxue Granules
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 19150703

Group type: EXPERIMENTAL
Intervention: GM‐CSF 10 microg/kg per day subcutaneously for 5 days
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 280
Study: 16283258

Group type: EXPERIMENTAL
Intervention: High-dose nicotine patch (35 mg)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 15520032

Group type: EXPERIMENTAL
Intervention: Matched vocabulary consultations
Number of subjects: 62

Group type: COMPARATOR
Intervention: Unmatched vocabulary consultations
Number of subjects: 62
Study: 11200381

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (ACA) for 5 days
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (ACA) for 10 days
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (ACA) for 5 days and 10 days
Number of subjects: 433
Study: 9311208

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol-fentanyl-ketamine (PFK)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isoflurane-nitrous oxide anesthesia (GOI)
Number of subjects: 12
Study: 8357556

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) and interferon-alpha (IFN-alpha)
Number of subjects: 36
Study: 3596768

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25‐50 mg b.i.d.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diltiazem (120‐180 mg b.i.d.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31236782

Group type: EXPERIMENTAL
Intervention: Sequential compression devices (SCDs) applied to the arm harboring the PICC
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no SCD applied)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sequential compression devices (SCDs) applied to the arm harboring the PICC (after accounting for crossovers)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no SCD applied, after accounting for crossovers)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Not applicable (symptomatic UE DVT and pulmonary embolism observed in patients not wearing SCD)
Number of subjects: 77
Study: 30702019

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine dosed 24-48 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term open-label study of deutetrabenazine
Number of subjects: 0
Study: 28489298

Group type: EXPERIMENTAL
Intervention: ALA‐PDT plus cetirizine 10 mg (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 20
Study: 26805505

Group type: EXPERIMENTAL
Intervention: Neurofeedback training (15 sessions over 5 weeks, 3 sessions per week)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 16
Study: 22907731

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) treatment in blacks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KCNJ1 variation in HCTZ-treated patients
Number of subjects: 0
Study: 21394017

Group type: EXPERIMENTAL
Intervention: Ex vivo technical skills training on low fidelity synthetic model
Number of subjects: 18

Group type: COMPARATOR
Intervention: No further contact with the models (Control)
Number of subjects: 18
Study: 18489017

Group type: EXPERIMENTAL
Intervention: therapist-delivered CRA treatment with vouchers
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: computer-assisted CRA treatment with vouchers
Number of subjects: 135

Group type: COMPARATOR
Intervention: standard treatment
Number of subjects: 135
Study: 20576719

Group type: EXPERIMENTAL
Intervention: Docetaxel/doxorubicin/cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorouracil/doxorubicin/cyclophosphamide
Number of subjects: 0
Study: 16353054

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study: 11865833

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 1800 mg daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9741018

Group type: EXPERIMENTAL
Intervention: Intravenous corticotrophin (ACTH) 120 U/day
Number of subjects: 88

Group type: COMPARATOR
Intervention: Hydrocortisone 300 mg/day
Number of subjects: 88
Study: 8275731

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 40 mg/kg/d, intravenously for 3 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo, intravenously for 3 days
Number of subjects: 61
Study: 2500462

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2 mg intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ro 15‐1788
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ro 15‐3505
Number of subjects: 0
Study: 4816852

Group type: EXPERIMENTAL
Intervention: Stripping of the long saphenous vein upwards
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stripping of the long saphenous vein downwards
Number of subjects: 30
Study: 30315436

Group type: EXPERIMENTAL
Intervention: SSMBI training
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 120
Study: 29957136

Group type: EXPERIMENTAL
Intervention: Spatone supplement
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 27347996

Group type: EXPERIMENTAL
Intervention: Palatinose™ (PSE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Maltodextrin (MDX)
Number of subjects: 20
Study: 24304594

Group type: EXPERIMENTAL
Intervention: Caffeine test
Number of subjects: 14

Group type: COMPARATOR
Intervention: Water drinking test
Number of subjects: 14
Study: 21639596

Group type: EXPERIMENTAL
Intervention: Alcohol (0.82 g/kg males; 0.74 g/kg females)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 720

Group type: COMPARATOR
Intervention: No-alcohol control beverage
Number of subjects: 720
Study: 19528265

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ceftazidime (200 mg/kg of body weight/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Short infusions of ceftazidime (200 mg/kg of body weight/day)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ceftazidime
Number of subjects: 69

Group type: COMPARATOR
Intervention: Short infusions of ceftazidime
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 69
Study: 17279435

Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysate
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Polysulfone membrane after 1 year of HD
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Switching from UFH to LMWH (n=4)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Continuation of UFH
Number of subjects: 63
Study: 15301659

Group type: EXPERIMENTAL
Intervention: Motivational enhancement for 12-step involvement (ME-12)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Brief advice (BA) to attend Alcoholics Anonymous
Number of subjects: 48
Study: 11154252

Group type: EXPERIMENTAL
Intervention: Patient follow up study design for screening evaluation
Number of subjects: 0
Study: 9581697

Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 1022
Study: 8160254

Group type: EXPERIMENTAL
Intervention: Ticarcillin and clavulanic acid
Number of subjects: 15
Study: 3182964

Group type: EXPERIMENTAL
Intervention: Low dose calcitriol (≤ 0.50 micrograms/day)
Number of subjects: 30
Study: 30082338

Group type: EXPERIMENTAL
Intervention: Public health intervention involving formative research, culturally based performing arts, competitions, and environmental clues, implemented over four intensive days per village.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Public health intervention (details not specified)
Number of subjects: 300
Study: 27172616

Group type: EXPERIMENTAL
Intervention: Wrist-worn accelerometers
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Hip-worn accelerometers
Number of subjects: 73
Study: 25399621

Group type: EXPERIMENTAL
Intervention: Blunt cannula
Number of subjects: 20

Group type: COMPARATOR
Intervention: Needle
Number of subjects: 20
Study: 24341368

Group type: EXPERIMENTAL
Intervention: Tailored implementation program for practice nurses including training, feedback on motivational interviewing, e-learning on cardiovascular risk management, and advice on screening for depressive symptoms.
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Tailored implementation program for practice nurses.
Number of subjects: 900

Group type: COMPARATOR
Intervention: Usual care provided by control practices.
Number of subjects: 900
Study: 20720348

Group type: EXPERIMENTAL
Intervention: Sibutramine plus L-carnitine
Number of subjects: 254

Group type: COMPARATOR
Intervention: Sibutramine
Number of subjects: 254
Study: 19040806

Group type: EXPERIMENTAL
Intervention: Papacárie gel (chemomechanical caries removal agent)
Number of subjects: 51
Study: 16368839

Group type: EXPERIMENTAL
Intervention: Stimulating catheter with 0.125% levobupivacaine (group S-125)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonstimulating catheter with 0.125% levobupivacaine (group NS-125)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Stimulating catheter with 0.0625% levobupivacaine (group S-0625)
Number of subjects: 48
Study: 12084589

Group type: EXPERIMENTAL
Intervention: PCI within 24 hours of enrollment
Number of subjects: 9461

Group type: EXPERIMENTAL
Intervention: PCI at 24 to 72 hours
Number of subjects: 9461

Group type: EXPERIMENTAL
Intervention: PCI at 3 to 7 days
Number of subjects: 9461

Group type: EXPERIMENTAL
Intervention: PCI at 8 to 30 days
Number of subjects: 9461
Study: 10426697

Group type: EXPERIMENTAL
Intervention: Mental stress during the mental task
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control sessions (without mental stress)
Number of subjects: 14
Study: 7559306

Group type: EXPERIMENTAL
Intervention: Tourette's syndrome (TS)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Chronic tic disorder
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 71
Study: 2191855

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: COMPARATOR
Intervention: Not treated with enalapril (control)
Number of subjects: 135
Study: 343806

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate ointment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 16
Study: 31724424

Group type: EXPERIMENTAL
Intervention: Mindfulness-based weight loss intervention (n = 100)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Active control components (n = 94)
Number of subjects: 194
Study: 28150436

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 26267600

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 43
Study: 24504761

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 23855170

Group type: EXPERIMENTAL
Intervention: Fuji VII (glass ionomer based)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Admira Seal (ormocer based)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of both sealants
Number of subjects: 50
Study: 21175439

Group type: EXPERIMENTAL
Intervention: oseltamivir 75 mg twice daily for 4.5 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: warfarin alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: oseltamivir + warfarin
Number of subjects: 20
Study: 18723329

Group type: EXPERIMENTAL
Intervention: Daptomycin, Linezolid, Quinupristin/Dalfopristin, Semisynthetic lipoglycopeptides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doripenem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polymyxins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic lock therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous intravenous administration of antibiotics
Number of subjects: 0
Study: 16640640

Group type: EXPERIMENTAL
Intervention: EDTA 17%
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EDTAC 17%
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Citric acid 10%
Number of subjects: 16